MindBio Therapeutics (FRA:WF60) Ending Cash Position: €0.04 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:WF60 MindBio Therapeutics Corp FRA:WF60
37 GF Score
Price €0.13
! 1 Warning Sign
View Full Analysis

What is MindBio Therapeutics Ending Cash Position?

MindBio Therapeutics FRA:WF60 37 Ending Cash Position is €0.04 Mil as of Mar. 2026. GuruFocus rates FRA:WF60 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

MindBio Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was €0.04 Mil.

MindBio Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 (€0.01 Mil) to Dec. 2025 (€0.24 Mil) but then declined from Dec. 2025 (€0.24 Mil) to Mar. 2026 (€0.04 Mil).

MindBio Therapeutics's annual Ending Cash Position declined from Jun. 2023 (€0.20 Mil) to Jun. 2024 (€0.09 Mil) and declined from Jun. 2024 (€0.09 Mil) to Jun. 2025 (€0.04 Mil).

MindBio Therapeutics Ending Cash Position Related Terms

MindBio Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for MindBio Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindBio Therapeutics Ending Cash Position Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
0.00 0.87 0.20 0.09 0.04

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.04 0.01 0.24 0.04
FRA:WF60
37GF Score
MindBio Therapeutics Corp FRA:WF60
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindBio Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MindBio Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=-0.012+0.048
=0.04

MindBio Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.208+-0.167
=0.04

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.04 Mil mean?
MindBio Therapeutics (FRA:WF60) has a Ending Cash Position of €0.04 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MindBio Therapeutics and its competitors.
Is MindBio Therapeutics' Ending Cash Position too high?
MindBio Therapeutics' current Ending Cash Position is €0.04 Mil. Overall, MindBio Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' Ending Cash Position compare to VRTX and REGN?
MindBio Therapeutics' Ending Cash Position of €0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MindBio Therapeutics and its competitors. MindBio Therapeutics's current Ending Cash Position is €0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (FRA:WF60) has a current Ending Cash Position of €0.04 Mil. The current Ending Cash Position is €0.04 Mil. MindBio Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For MindBio Therapeutics (FRA:WF60), the current Ending Cash Position is €0.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindBio Therapeutics Business Description

Other Exchanges MBIO:Canada
Address 91-97 William Steet, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
37GF Score

Get the complete analysis for FRA:WF60

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price